CD274 and neoplasm: PARPi exposure was treated as a treatment covariate rather than an outcome; its association with reduced risk is biologically plausible—PARPi can remodel the tumor immune microenvironment, upregulate PD-L1, and activate innate immune pathways—yet confounding must be considered in nonrandomized analyses (30).